Literature DB >> 2009235

Concentrations of VP16 and VM26 in human brain tumors.

M Zucchetti1, C Rossi, R Knerich, M G Donelli, G Butti, V Silvani, P Gaetani, M D'Incalci.   

Abstract

VP16 and VM26 were determined by high pressure liquid chromatography in intracerebral tumors, adjacent normal brain tissue, plasma and CSF samples from 24 patients given the two drugs before surgical resection of the tumor. The drugs were administered at doses of 100-150 mg/m2 as a 1-hour i.v. infusion, between 1.5 and 12 hours before surgery. Concentrations of VP16 ranged between 1.05 and 3.28 micrograms/g in tumors in the series of patients who received the drug 1.5-3 hours before surgery and between less than 0.05 and 1.12 micrograms/g in four patients who received the drug 9-13 hours before surgery. Tumor concentrations of VM26 also varied, ranging from less than 0.05 to 1.68 micrograms/g between 1.5 and 12 hours before surgery. VP16 and VM26 in the apparently normal brain tissue surrounding the tumor were low or undetectable except in one patient who had received radiotherapy, in whom we found 3.1 micrograms/g.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2009235     DOI: 10.1093/oxfordjournals.annonc.a057826

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  9 in total

Review 1.  Do anticancer agents reach the tumor target in the human brain?

Authors:  M G Donelli; M Zucchetti; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma.

Authors:  Adam M Sonabend; Arthur S Carminucci; Benjamin Amendolara; Mukesh Bansal; Richard Leung; Liang Lei; Ronald Realubit; Hai Li; Charles Karan; Jonathan Yun; Christopher Showers; Robert Rothcock; Jane O; Andrea Califano; Peter Canoll; Jeffrey N Bruce
Journal:  Neuro Oncol       Date:  2014-03-16       Impact factor: 12.300

Review 3.  Tissue concentration of systemically administered antineoplastic agents in human brain tumors.

Authors:  Marshall W Pitz; Arati Desai; Stuart A Grossman; Jaishri O Blakeley
Journal:  J Neurooncol       Date:  2011-03-12       Impact factor: 4.130

4.  Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma.

Authors:  A Boiardi; A Silvani; I Milanesi; M Botturi; G Broggi
Journal:  Ital J Neurol Sci       Date:  1992-12

Review 5.  Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances.

Authors:  Nancy D Doolittle; Leslie L Muldoon; Aliana Y Culp; Edward A Neuwelt
Journal:  Adv Pharmacol       Date:  2014-08-22

Review 6.  Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.

Authors:  Jann N Sarkaria; Leland S Hu; Ian F Parney; Deanna H Pafundi; Debra H Brinkmann; Nadia N Laack; Caterina Giannini; Terence C Burns; Sani H Kizilbash; Janice K Laramy; Kristin R Swanson; Timothy J Kaufmann; Paul D Brown; Nathalie Y R Agar; Evanthia Galanis; Jan C Buckner; William F Elmquist
Journal:  Neuro Oncol       Date:  2018-01-22       Impact factor: 12.300

Review 7.  Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy.

Authors:  Amol Mehta; Chidiebere U Awah; Adam M Sonabend
Journal:  Front Neurol       Date:  2018-06-20       Impact factor: 4.003

8.  Ribosomal protein S11 influences glioma response to TOP2 poisons.

Authors:  Chidiebere U Awah; Li Chen; Mukesh Bansal; Aayushi Mahajan; Jan Winter; Meeki Lad; Louisa Warnke; Edgar Gonzalez-Buendia; Cheol Park; Daniel Zhang; Eric Feldstein; Dou Yu; Markella Zannikou; Irina V Balyasnikova; Regina Martuscello; Silvana Konerman; Balázs Győrffy; Kirsten B Burdett; Denise M Scholtens; Roger Stupp; Atique Ahmed; Patrick Hsu; Adam M Sonabend
Journal:  Oncogene       Date:  2020-06-11       Impact factor: 9.867

Review 9.  Current and emerging therapies for primary central nervous system lymphoma.

Authors:  Yan Yuan; Tianling Ding; Shu Wang; Hong Chen; Ying Mao; Tong Chen
Journal:  Biomark Res       Date:  2021-05-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.